Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA panel: Let anti-NGF studies move forward, despite 'severe' joint risks

This article was originally published in Scrip

Executive Summary

After hearing pleas from patients and experts that the available therapies to treat severe pain are inadequate, advisers to the US FDA said they were not ready to slam the door on an experimental class of drugs, known as anti-nerve growth factors (anti-NGFs), which have been linked to serious adverse effects, including bone and joint deterioration leading to joint-replacement surgery.


Related Content

Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class
Regeneron Partners NGF Antibody With Teva To Mitigate Risks
Regeneron Revives NGF Inhibitor With Phase II/III Data; Safety Issue Remains


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts